Brief Recap and Updates on the MarketsAnalyst Actions and Comments - TDOC, HZNP, EPZMDow -248.91 at 24758.12, Nasdaq -14.20 at 7496.80, S&P -15.83 at 2749.48Stocks declined Wednesday amid more tariff talk and the possibility of a trade war. Larry Kudlow has been named as President Trump's top economic advisor replacing Gary Cohn. Trump and Kudlow will be looking at ways to reduce China's trade surplus. The S&P 500 is testing its 50-day moving average. On the chart, the full stochastic has peaked and is declining. The question will be does the 50-day MA hold up.Nasdaq Composite: +8.6% YTDS&P 500: +2.8% YTDDow Jones Industrial Average: +0.2% YTDRussell 2000: +3.2% YTDEarly this morning, Teladoc (TDOC) was downgraded to Hold from a Buy at Deutsche Bank and maintains a $45 price target. Valuation was given as the reason as TDOC has gained 23% year-to-date already. However, after the close on Wednesday KeyBanc raised their price target to $50.An article has just be written about them here: Calling the Doctor at TeladocAlso early Thursday morning, Cantor Fitzgerald keeps its Overweight rating on Horizon Pharma (HZNP), $17 price target. The analyst does raise questions about the adoption of Horizon's Krystexxa drug for the treatment of gout.On Wednesday, a few analysts made updates to their coverage of Epizyme (EPZM) after the company reported earnings.SunTrust's analyst raised his price target on Epizyme to $27 while maintaining a BUY rating. Price Target was lowered to $25 at Oppenheimer, but they stated the 4Q Report provided a positive clinical update.Price Target was raised to $24 at Leerink Partners.At Citi, the price target was raised to $30.00 from $22.00 while keeping its Buy rating. Multiple avenues for upside was cited.Wedbush raised its price target to $24.00 from $21.00 and maintained its Outperform rating.Disclosure: I may trade next week in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the like (thumbs up) button. Feel free to leave any comments and follow us.